ACADIA Pharmaceuticals Revenue by Product

Period Ending	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
NUPLAZID	680.09M	661.74M	650.67M	620.90M	590.42M	576.06M	560.67M	549.21M
NUPLAZID Growth	15.19%	14.87%	16.05%	13.05%	8.97%	9.17%	7.77%	6.17%
DAYBUE	391.42M	381.53M	370.00M	361.31M	338.78M	314.43M	253.10M	-	-	-	-	-	-	-	-	-	-	-	-	-
DAYBUE Growth	15.54%	21.34%	46.19%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.